FCER1A and asthma: In conclusion, our findings suggest that omalizumab (anti-IgE) treatment reduces the activation of DCs and monocytes in asthma patients by downregulating not only surface FcεRI but also several key surface receptors, including CCR7, HLA-DR, and costimulatory molecules that contribute to allergic inflammatory responses elicited by DCs and monocytes.